In a significant development in the field of obesity treatment, Lilly’s Zepbound (tirzepatide) has shown remarkable results in the SURMOUNT-4 study. Published in The Journal of the American Medical Association (JAMA), the study details how Zepbound injection led to superior mean percent changes in body weight compared to placebo among adults with obesity or overweight, […]
In a strategic move to strengthen its position in the life sciences sector, Eli Lilly and Company (NYSE: LLY) has revealed plans to inaugurate its first-ever Lilly Gateway Labs facility in San Diego, California, in the first half of 2024. This initiative marks the company’s third such facility, joining its existing sites in San Francisco […]
Eli Lilly and Company (NYSE: LLY) unveiled its plan to build a $2.5 billion state-of-the-art manufacturing site in Alzey, Rhineland-Palatinate, Germany. This new facility, earmarked for parenteral (injectable) product and device manufacturing, will significantly bolster Lilly’s capacity to meet rising global demand for its diabetes and obesity medications. A Commitment to Global Health and Innovation […]
The U.S. Food and Drug Administration has granted approval to Eli Lilly’s Zepbound (tirzepatide) injection, making it the only obesity treatment that activates both GIP and GLP-1 hormone receptors. This medication is tailored for adults with obesity or overweight conditions associated with weight-related medical issues such as hypertension and type 2 diabetes. Zepbound is recommended […]
The U.S. Food and Drug Administration (FDA) has sanctioned Eli Lilly and Company’s Omvoh (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), making it the pioneering IL-23p19 antagonist for treating moderate to severe ulcerative colitis in adults. This groundbreaking treatment is distinguished for targeting the p19 subunit of IL-23, a catalyst in UC-related inflammation. An Innovative […]
Eli Lilly (Lilly) has disclosed the results from two pivotal Phase 3 studies, LIBRETTO-431 and LIBRETTO-531, evaluating the efficacy of Retevmo in treating patients with specific types of advanced or metastatic cancers. These revelations were spotlighted during the ESMO Congress 2023 and simultaneously found a place in the esteemed New England Journal of Medicine. Key […]
Eli Lilly and Company (NYSE: LLY), a pharmaceutical leader, unveiled that mirikizumab, its cutting-edge interleukin-23p19 antagonist, has demonstrated its prowess against placebo in the critical VIVID-1 Phase 3 trial. The study, crucial for those with moderately to severely active Crohn’s disease, has established mirikizumab as a beacon of hope in the treatment landscape. Striking Results […]
Eli Lilly and Company (NYSE: LLY) is set to acquire POINT Biopharma Global, Inc. (NASDAQ: PNT), a leading radiopharmaceutical firm, marking a significant leap in cancer treatment innovations. This acquisition integrates POINT Biopharma Global’s radioligand therapies, which precisely target cancer cells, promising enhanced tumor efficacy and minimized impact on healthy tissues. POINT Biopharma Global’s cutting-edge […]
Eli Lilly and Company (NYSE: LLY) has announced a recent development regarding its biologic license application (BLA) for lebrikizumab, a treatment aimed at addressing moderate-to-severe atopic dermatitis, commonly known as eczema. The U.S. Food and Drug Administration (FDA) has issued a complete response letter, citing specific findings from a multi-sponsor inspection of a third-party contract […]
Eli Lilly and Company (NYSE: LLY) unveiled exceptional results from their LIBRETTO-531 study of Retevmo (selpercatinib), setting a new standard in the treatment of advanced RET-mutant medullary thyroid cancer (MTC). The Phase 3 clinical trial distinctly highlights Retevmo’s superiority over existing first-line treatments, namely multikinase inhibitors cabozantinib and vandetanib. Retevmo demonstrated a statistically significant and […]